Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Pfizer Reports China Trial Results for Lyrica

publication date: Aug 13, 2014
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Pfizer reported mixed results from two China trials of Lyrica®, an anti-seizure drug that is also effective against some forms of neuropathic and chronic pain. Lyrica successfully reduced pain in a Phase IV follow-up study of patients with postherpetic neuralgia (PHN), the pain that follows shingles. But Lyrica did not meet its endpoints in a Phase III trial among patients with painful diabetic peripheral neuropathy (pDPN). More details....

Stock Symbol: (NYSE: PFE)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...